Orphan drug developer Minoryx raises 51m
Minoryx Therapeutics SL has closed a 51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
G7 heads call for decarbonisation of industry
/in News/by Thomas GabrielczykG7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle the triple global crisis of climate change, biodiversity loss and pollution".
Ellipses Pharma licences SRB22 from SunRock Biopharma
/in News/by Thomas GabrielczykEllipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.
Evotec signs contracts with Almirall and Sernova
/in News/by Thomas GabrielczykHamburg-based CRO Evotec SE has inked a drug development partnership with Spanish Almirall SA in dematology.
Avantium gets EU grant
/in News/by Thomas GabrielczykAvantium NV will get a 3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.
Enzymaster raises $45m in Series C round
/in News/by Thomas GabrielczykBiocatalysis expert Enzymaster (Germany, China, Singapore) has cashed in $45m to expand its production capacity of engineered biosynthetic enzymes.
EU starts consultation on novel plant breeding methods
/in News/by Thomas GabrielczykThe EU Commission has launched its final consultation on the deregulation of new breeding techniques in agriculture.
Hot of the press: BIOTECH Insight Newsletter
/in News/by Thomas GabrielczykDeutsche Börse report key growth figures of the German biotech sector in 2021 in BIOTECH Insight, its new online information service published in collaboration with BIOCOM AG.
Engimmune Therapeutics raises CHF15.5m in seed financing
/in News/by Thomas GabrielczykCancer specialist Engimmune Therapeutics has raised CHF15.5m in a seed financing to expand its pipeline of T-cell receptor therapeutics.
Switzerland shows sustained growth of biotech sector
/in News/by Thomas GabrielczykThe Swiss Biotech sector has again attracted record-breaking investments in 2021, according to the Swiss Biotech Report that was presented at the Swiss Biotech Day 2022 in Basel.